Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Adma Biologics (ADMA) Long-Term Debt Issuances (2017 - 2023)

Historic Long-Term Debt Issuances for Adma Biologics (ADMA) over the last 8 years, with Q4 2023 value amounting to $135.0 million.

  • Adma Biologics' Long-Term Debt Issuances changed N/A to $135.0 million in Q4 2023 from the same period last year, while for Dec 2024 it was $135.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $135.0 million for FY2023, which is 1103.79% down from last year.
  • Per Adma Biologics' latest filing, its Long-Term Debt Issuances stood at $135.0 million for Q4 2023.
  • Adma Biologics' 5-year Long-Term Debt Issuances high stood at $151.8 million for Q1 2022, and its period low was $12.5 million during Q1 2020.
  • Its 4-year average for Long-Term Debt Issuances is $71.8 million, with a median of $45.0 million in 2019.
  • Within the past 5 years, the most significant YoY rise in Adma Biologics' Long-Term Debt Issuances was 7222.22% (2020), while the steepest drop was 7222.22% (2020).
  • Over the past 4 years, Adma Biologics' Long-Term Debt Issuances (Quarter) stood at $45.0 million in 2019, then plummeted by 66.67% to $15.0 million in 2020, then surged by 911.67% to $151.8 million in 2022, then decreased by 11.04% to $135.0 million in 2023.
  • Its last three reported values are $135.0 million in Q4 2023, $151.8 million for Q1 2022, and $15.0 million during Q4 2020.